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Background: Process of accelerated atherosclerosis specific for uremia increases cardiovascular risk in patients with
chronic kidney disease (CKD) and may be influenced by the different structure of arteries. The study assesses the
influence of traditional and novel risk factors on calcification of coronary arteries (CAC) and abdominal aorta (AAC)
in hemodialysis patients (HD).
Methods: CAC and AAC were assessed by CT in 104 prevalent adult HD and 14 apparently healthy subjects with
normal kidney function (control group). Mineral metabolism parameters, plasma levels of FGF-23, MGP,
osteoprotegerin, osteopontin, fetuin-A, CRP, IL-6 and TNF-α were measured.
Results: CAC and AAC (calcification score ≥ 1) were found in 76 (73.1%) and 83 (79.8%) HD respectively, more
frequent than in the control group. In 7 HD with AAC no CAC were detected. The frequency and severity of
calcifications increased with age. Both CAC and AAC were more frequently detected in diabetics (OR = 17.37 and
13.00, respectively). CAC score was significantly greater in males. CAC and AAC scores were correlated significantly
with pack-years of smoking and plasma osteoprotegrin levels. However the independent contribution of plasma
osteoprotegerin levels was not confirmed in multiple regression analysis. Age (OR = 1.13) and hemodialysis vintage
(OR = 1.14) were the independent risk factor favoring the occurrence of CAC; while age (OR = 1.20) was the only
predictor of AAC occurrence in HD.
Conclusions: 1. AAC precedes the occurrence of CAC in HD patients. 2. The exposition to uremic milieu and
systemic chronic microinflammation has more deteriorative effect on the CAC than the AAC.
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Cardiovascular diseases remain the leading cause of
morbidity and mortality, regardless of the significant
progress of revascularization procedures and their acces-
sibility, in patients with chronic kidney disease (CKD).
In CKD patients, especially in those on dialysis therapy,
the risk of cardiovascular death is particularly high, 10–
20 times greater than in the general population [Foley
et al. [1]]. At least in part the increased risk is related to* Correspondence: chj@poczta.fm
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reproduction in any medium, provided the oraccelerated development of atherosclerosis, that cannot
be only attributed to the presence of the traditional risk
factors such as age, sex, smoking, obesity, dyslipidemia,
hypertension and diabetes. In 1974, Lindner et al. [2]
described the phenomenon of the accelerated athero-
sclerosis in dialysis patients, that has not been fully
explained for nearly forty years. The development of
accelerated atherosclerosis and typical for CKD calcifica-
tion of tunica media, labeled as Monckeberg’s sclerosis
is associated with transformation of vascular smooth
muscle cells (VSMCs) into osteoblast-like cells, able to
synthesize bone matrix protein-2 (BMP-2), matrix Gla
protein (MGP) and osteopontin [3]. Osteoblasts in vas-
cular wall may also arise from mesenchymal cells -Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be converted into bone cells [4].
The process of vascular calcification of systemic arter-
ies probably differs in muscular and elastic vessels. High
number of VSMCs in the tunica media of muscle arter-
ies seems to predispose, whereas high content of elastic
fibers in elastic large arteries may protect against
Monckeberg’s calcifications development. It should be
stress, that degradation of elastic fibers by matrix metal-
loproteinases with generation of soluble elastin peptides
may stimulate VSMCs transformation into osteoblast-
like cells [5]. This process of vascular calcification is
similar to the process of bone formation.
Recent evidence suggests that the interaction of trad-
itional (i.e., Framingham: age, lifestyle, diabetes, hyper-
tension, dyslipidemia) and uremia-related, so could
novel (e.g. hyperphosphataemia, high calcium x phos-
phorus product, hyperparathyroidism, oxidative stress,
systemic inflammation, protein-energy wasting, asym-
metric dimethylarginine, P-cresol, fetuin A) cardiovascu-
lar risk factors contribute in excessive and accelerated
vascular calcifications in CKD patients [6]. In elderly
CKD patients, traditional cardiovascular risk factors
probable participate more than the novel ones in the
development of vascular calcifications. Shlipak et al.
showed that traditional cardiovascular risk factors had
larger associations with cardiovascular mortality than
novel risk factors in elderly CKD (non-dialysis) persons
[7]. However, whether their role in the development of
calcification in muscular and elastic vessels is similar is
not yet known.
Therefore the aim of the present study was to assesses
the influence of traditional and novel risk factors on cal-
cification of coronary arteries and abdominal aorta in
hemodialysis patients.
Methods
One-hundred-four stable, prevalent hemodialysis patients
(HD; 56 males and 48 females) from single HD unite
(recruited from 2009 to 2011) and 14 apparently healthy
subjects with normal kidney function (control group) were
included into the study. Patients on HD therapy for less
than 3 months, any acute illnesses within a month,
cancers, liver cirrhosis and treated with cinacalcet were
excluded from the study. Study protocol was approved by
the Bioethics Committee of Medical University of Silesia
(KNW-6501-37/I/08). All patients gave informed consent
for participation in the study.
All patients from the HD group were on hemodialysis
3 times per week for 4–5 hours sessions. Bicarbonate-
buffered dialysate fluid containing 2–3 mmol/L potas-
sium, 1,25 mmol/L calcium, 0.75 mmol/L of magnesium
and low-flux polysulfone or cuprofane dialysis membranes
were used in all patients. HD patients characteristicsincluding CKD causes, duration of hemodialysis therapy,
Kt/V and comorbidities are given in Table 1.
The control group consisted of 14 apparently healthy
adults in similar age – range from 23 to 85 years (6
males and 8 females) with normal kidney function
(eGFR-MDRD > 90 ml/min/1.73 m2) and without signifi-
cant albuminuria.
The study protocol assumed anthropometric measure-
ments, blood sampling performed during the morning
before computed tomography (CT) scanning after
overnight fast. In addition monthly, routinely measured
parameters (complete blood count, serum concentra-
tions of albumin, urea, calcium, phosphorous, intact
parathyroid hormone, sodium, potassium, total, LDL
and HDL cholesterol and triglycerides) were obtained
before mid-week HD session. Plasma samples for estima-
tion of CRP, IL-6, TNF-α, fetuin-A, osteoprotegerin, osteo-
pontin, osteokalcin, MGP, intact fibroblast growth factor
23 (FGF-23) and 25(OH)D3 were stored frozen at −70°C
till assessment.Measurement calcification score with multislice spiral
computed tomography (MSCT)
Measurement of coronary arteries (CAC) and abdominal
aorta (AAC) calcifications was performed with 64-row
CT scanner Aquilion 64 (Toshiba Medical Systems Cor-
poration) equipped with an integrated ECG monitor and
appropriate software for testing and evaluation of cal-
cium Agatston score.
Scanning was done in sequential 3 mm thick layers
(for aorta starting scanning 3 cm proximal to the bifur-
cation of the aorta). After the test, the images were
transferred to a dedicated workstation VITREA 2 (Vital
Images, Inc.) equipped with program to calculate Agat-
ston score. Calculations were done automatically after
determination by the radiologist the calcification in the
arterial wall in appropriate scans. The results were read-
out of the workstation monitor.Laboratory analyses
Routine laboratory measurements were performed in
hospital laboratory (Synchron Cx-9, Beckman Coulter
Inc., Fullerton, CA, U.S.). Serum high sensitivity CRP
was measured by nephelometry (Siemens Healthcare
Diagnostics, Deerfield, IL, U.S.) with a lower limit of
sensitivity of 0.2 mg/l.
Plasma concentrations of IL-6 (R&D System, Minnesota,
MN, U.S.), TNF-α (R&D System, Minnesota, MN, U.
S.), MGP (Biomedica, Wien, Austria), fetuin-A and
osteopontin (DRG, Mountainside, NJ, U.S.), osteo-
protegerin (Biovendor, Modřice, Czech Republic),
osteocalcin (Quidel, San Diego, CA, U.S.), 25-OH-D3
(Immundiagnostik, Bensheim, Austria), and FGF-23
Table 1 Demographic and clinical characteristics of study participants (mean & 95% CI)
Hemodialysis group Control group Statistical
significance(N = 104) (N = 14)
Age (years) 53.6 (50.3-56.9) 54.6 (45.1-64.1) 0.93
Gender (male/female) 56/48 6/8 0.63
Body mass index (kg/m2) 24.9 (23.3-26.6) 24.7 (23.9-25.6) 0.82
Obesity (BMI≥ 30 kg/m2) (n/%) 11 / 10.6 0 0.43
Smokers (n/%) 62 / 59.6 1 / 7.1 <0.001
Smoking burden (pack-years) 15 (12–18)
Family burden (n/%) 32 / 30.8 NA.
Primary cause of CKD (n/%)
Diabetes 11 / 10.6
Hypertension 4 / 3.8
Nephrolithiasis 3 / 2.9
Autosomal Dominant Polycystic Kidney Disease (ADPKD) 6 / 5.8
Ischemic nephropathy 5 / 4.8
Glomerulonephritis 50 / 48.1
Urinary tract infection 6 / 5.8
Amyloidosis 3 / 2.9
Other or unknown 16 / 15.4
Time on dialysis (months) 45 (33–54)
Kt/V (per HD session) 1.29 (1.25-1.34)
Co-morbidity (%)
Hypertension 87 / 84.5 0
Diabetes 19 / 18.3 0
Coronary artery disease 35 / 33.7 0
Stroke 9 / 8.7 0
Past kidney transplantation 18 / 17.3 -
Pharmacotherapy (n/%)
Antihypertensive 79 / 76.0
No of antihypertensive drugs (n) 2.0 (1.7-2.2)
Oral anti-diabetic* 5 / 26.3
Insulin* 14 / 73.7
Antiplatelet 52 / 50.0
Oral anticoagulant 9 / 8.7
Statins 18 / 17.3
Fibrates 0
Oral phosphorous binders 102 / 98.1
Carbonate calcium dose (g/day) 3.3 (2.9-3.7)
Sevelamer hydrochloride (g/day) 0
Alfacalcidol 82 / 78.8
Alfacalcidol dose (μg/week) 2.5 (1.1-3.8)
* for patients with diabetes.
NA. – not available.
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Figure 1 Frequency of coronary and abdominal aorta
calcifications.
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mined by ELISA.
Data analysis
Arterial hypertension was defined as the predialysis blood
pressure values ≥140/90 mmHg or antihypertensive
medication. Dyslipidemia was defined as the concen-
tration of total cholesterol ≥ 5.0 mmol/L or LDL-choles-
terol ≥ 3.0 mmol/L or low HDL-cholesterol (< 1.0 mmol/L
for men and < 1.2 mmol/L for women) or trigly-
cerides ≥ 1.7 mmol/L or lipid lowering therapy. Obes-
ity was diagnosed according WHO criteria.
On the basis of CAC Agatston score we classified cal-
cifications in patients according to Rumberger et al.
criteria as: mild (1–10), moderate (11–100), large (101–
400) and massive (> 400) [8]. The severity of AAC were
scored according own classification, based on an expo-
nential scale: mild (1–100), moderate (101–1000) and
large (> 1000).
HD patients were divided into 3 subgroups: with
calcification in both locations (CAC and AAC), with
isolated aorta calcifications (AAC only) and without
calcifications.
Statistical analysis
Statistical analysis was performed with STATISTICA
10.0 PL Stat Soft Corporation software (www.statsoft.
com). Results are given as mean values with 95% con-
fidence intervals (95% CI). For comparison of groups,
we used the χ2 test and χ2 test for trend (qualitative
variables) and ANOVA, followed by Tukey’s test or
U-Mann–Whitney test, as appropriate (quantitative
variables). Correlation coefficient was calculated according
to Spearman. Univariate and multivariate backward step-
wise logistic regression analysis were performed including
factors potentially favoring or preventing the calcification
development, including age, hemodialysis vintage, gender,
hypertension, diabetes, current smoking or pack-years ex-
position, levels of phosphorous, calcium, PTH, 25(OH)D3,
osteoprotegerin, MGP, CRP, IL-6, TNF-α. All variables
were tested for the presence of multi co-linearity,
which was assessed with the variance inflation factor
and the conditional index. p < 0.05 was considered as
statistically significant.
Results
Characteristics of study groups is given in Table 1. CAC
(calcification score ≥ 1) were found in 76 HD patients
(73.1%), and 5 in the control group (35.7%) - p <0.01
(with Yates correction). Among HD patients 6 had mild
(5.8%), 10 moderate (9.6%), 12 large (13.5%) and 48
massive (46.1%) CAC.
Within the abdominal aorta calcifications were
detected in 83 HD patients (79.8%) and 6 in the controlgroup (42.9%) - p <0.01 (with Yates correction). Among
HD patients mild AAC were found in 7 subjects (6.7%),
moderate in 19 (18.3%) and severe in 57 (54.8%). The
frequency of calcifications increased with age (Figure 1).
The severity of CAC and AAC was significantly
greater in HD patients than in the control group
(Table 2). Among HD patients, AAC was detected from
age of 25 years, while CAC from age of 28 years. CAC
score (CACS) was significantly higher in males than in
females [1196 (720–1672) vs. 644 (324–964), p = 0.001],
while AAC score was similar [2971 (1968–3974) vs.
2544 (1558–3530), p = 0.49; respectively]. Calcifications
in both locations were detected in each patient diag-
nosed with diabetes [OR = 17.37 (1.01-298.56), p = 0.049
and 13.00 (0.75-224.58, p = 0.08) for CAC and AAC re-
spectively], and were more severe than in not diabetics
[1464 (704–2224) vs. 825 (502–1147), p = 0.001 and
4987 (2861–7112) vs. 2279 (1591–2967), p < 0.001; re-
spectively]. Diabetic patients were significantly older [64
(58–70) vs. 51 (48–59) years, p = 0.003] but not HD
vintage was similar. There was no association between
occurrence of calcifications and smoking or dyslipide-
mia. Among smokers there were correlations between
pack-years and CAC as well as AAC scores (R = 0.37,
p = 0.002 and R = 0.36, p = 0.002; respectively).
All but two HD patients, with CAC detected, had
AAC. However, in 7 patients with AAC no CAC was
detected (kappa coefficient 0.798, 95% CI 0.708-0.870).
The correlation between CAC and AAC scores was
slightly stronger for control group (R = 0.70, p <0.001 in
HD and R = 0.78, p = 0.001 in controls).
Characteristics of patients with calcifications
Patients with detectable both CAC and AAC were
29 years older and had longer history of HD therapy
than those without calcifications (Table 3). This group
included all diabetics, all but 2 with CAC, the highest
percentage of patients with hypertension and low PTH
Table 2 Calcification scores and biochemical characteristics of study groups (mean & 95% CI)
Hemodialysis group Control group Statistical
significance(N = 104) (N = 14)
CACS 941 (645–1238) 182 (0–405) <0.001
AACS 2773 (2078–3470) 431 (0–945) <0.001
Hematocrit (%) 33.6 (32.8-34.5) 40.9 (38.5-43.3) <0.001
Hemoglobin (g/dL) 11.1 (10.8-11.4) 14.0 (13.2-14.8) <0.001
Albumin (g/dL) 3.87 (3.76-3.97) 4.06 (3.82-4.31) 0.26
Creatinine (μmol/L) NA 77 (66–88)
Total cholesterol (mmol/L) 4.63 (4.37-4.88) 5.43 (4.88-5.97) 0.02
LDL cholesterol (mmol/L) 2.61 (2.39-2.83) 3.17 (2.71-3.64) 0.04
HDL cholesterol (mmol/L) 1.14 (1.06-1.23) 1.54 (1.26-1.83) 0.002
Triglycerides (mmol/L) 1.94 (1.67-2.22) 1.44 (0.72-2.15) 0.02
Dyslipidemia (n /%) 75 / 72.1 11 / 78.6 0.85
Calcium (mmol/L) 2.17 (2.14-2.20) 2.26 (2.22-2.31) 0.02
Phosphorous (mmol/L) 1.88 (1.74-2.03) 1.04 (0.95-1.13) <0.001
Parathyroid hormone (pg/mL) 409 (313–506) 50 (40–61) <0.001
25(OH)D3 (ng/mL) 22.9 (17.7-28.1) 28.0 (16.5-39.4) 0.34
iFGF-23 (ng/mL) 662.9 (464.3-861.4) 6.3 (5.6-6.9) <0.001
Osteocalcin (pmol/L) 39.2 (31.1-47.3) 5.4 (3.9-6.8) <0.001
Osteopontin (ng/mL) 103.2 (93.5-112.8) 27.8 (23.8-31.8) <0.001
Osteoprotegerin (pmol/L) 14.7 (12.0-17.3) 5.0 (3.8-6.1) <0.001
Matrix GLA protein (nmol/L) 11.1 (10.2-11.9) 13.6 (12.2-14.9) 0.01
Fetuin-A (g/L) 0.63 (0.55-0.70) 0.70 (0.56-0.84) 0.13
CRP (mg/L) 12.6 (9.2-16.1) 1.2 (0.8-1.6) <0.001
IL-6 (pg/mL) 7.3 (5.4-9.1) 2.6 (1.3-3.8) <0.001
TNF-α (pg/mL) 10.6 (8.8-12.4) 1.8 (1.0-2.5) <0.001
NA – not available.
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the lowest 25(OH)D3 and highest osteoprotegerin and
CRP plasma levels.
The subgroup of patients with isolated AAC was
younger (average of 12 years) than the subgroup with
calcifications in both locations examined. This subgroup
had also markedly higher plasma osteoprotegerin level
(Tab. 3).
Serum phosphorous level and CaxP product were
comparable in all HD study subgroups.Univariate correlations
In patients with CAC, CACS was significantly associated
with the HD vintage (R = 0.27, p = 0.02), pack-years of
smoking (R = 0.37, p = 0.002), duration of hypertension
therapy (R = 0.28, p = 0.03), plasma levels of osteoprote-
gerin (R = 0.32, p = 0.01) and MGP (R = 0.305, p = 0.03).
The severity of AAC was only related to age (R = 0.44, p
< 0.001), plasma level of osteoprotegerin (R = 0.32, p =
0.003) and pack-years of smoking (R = 0.36, p = 0.002).There were significant inverse correlation between age
and serum phosphorous level (R = − 0.41, p < 0.001),
CaxP product (R = −0.40, p < 0.001), PTH (R = −0.25,
p = 0.01).
Moreover, there was a strong correlation between age
and plasma osteoprotegerin level (R = 0.60, p < 0.001) as
well as IL-6 (R = 0.28, p = 0.03).
Multiple logistic regression analysis
The multiple logistic regression analysis showed that
only age (per year) [OR = 1.13 (1.07-1.18), p < 0.001] and
time on HD therapy (per year) [OR = 1.14 (1.00-1.34),
p = 0.04] were independent risk factors favoring the oc-
currence of CAC; while age [OR = 1.20 (1.11-1.30), p <
0.001] was the only predictor of the AAC occurrence in
HD patients.
Discussion
The results of our study demonstrate that AAC precedes
the occurrence of CAC and reveal differences in factors
favoring their development. Age and HD vintage was
Table 3 Comparison of subgroups according localization of CAC and AAC (mean & 95% CI)
AAC and CAC Isolated AAC No calcifications ANOVA
(N = 76) (N = 7) (N = 19)
Age (years) 60 (57–63) 48 (33–63) 31 (27–34) <0.001
Gender (male/female) 41/35 4/3 10/9 0.95
Smoking (n /%) 45 / 59.2 5 / 71.4 12 / 63.2 0.67
Diabetes (n /%) 19 / 25.0 0 0 0.001
Hypertension (n /%) 68 / 89.5 6 / 85.7 13 / 68.4 0.02
Coronary artery disease (n /%) 33 / 42.3 2 / 28.6 0 <0.001
Time on dialysis (months) 45 (32–59) 22 (10–34) 36 (15–56) 0.48
Kt/V 1.30 (1.25-1.35) 1.24 (0.93-1.54) 1.31 (1.20-1.42) 0.75
Body mass index (kg/m2) 25.2 (24.3-26.2) 23.0 (18.9-27.2) 23.1 (20.9-25.3) 0.09
Hemoglobin (g/dL) 11.1 (10.7-11.4) 11.4 (10.4-12.5) 11.0 (10.2-11.8) 0.80
Albumin (g/dL) 3.82 (3.70-3.94) 3.75 (3.21-4.30) 4.16 (3.91-4.29) 0.08
Total cholesterol (mmol/L) 4.78 (4.48-5.08) 4.26 (3.90-4.61) 4.08 (3.40-4.77) 0.09
LDL cholesterol (mmol/L) 2.75 (2.50-3.01) 2.44 (1.91-2.98) 2.19 (1.63-2.75) 0.12
HDL cholesterol (mmol/L) 1.16 (1.05-1.27) 1.05 (0.89-1.21) 1.11 (0.93-1.29) 0.76
Triglycerides (mmol/L) 2.00 (1.67-2.32) 1.75 (0.94-2.56) 1.52 (1.27-1.77) 0.32
Dyslipidemia (n /%) 57 / 75.0 3 / 42.9 13 / 68.4 0.37
Calcium (mmol/L) 2.17 (2.13-2.21) 2.22 (2.09-2.36) 2.16 (2.07-2.25) 0.68
Phosphorous (mmol/L) 1.78 (1.62-1.94) 1.94 (1.27-2.61) 2.16 (1.78-2.54) 0.12
Phosphorous >1.77 mmo/L (n /%) 40 / 52.6 3 /42.9 14 /73.7 0.14
CaxP (mmol2/L2) 3.84 (3.49-4.18) 4.31 (2.26-5.77) 4.64 (3.84-5.43) 0.12
PTH (pg/mL) 364 (263–464) 310 (138–481) 577 (225–928) 0.22
PTH <100 pg/mL (n /%) 20 / 25.6 0 2 / 10.5 0.06
25(OH)D3 (ng/mL) 19.2 (14.2-24.2) 24.2 (12.7-34.9) 29.2 (17.4-40.9) 0.04
iFGF-23 (ng/mL) 638.0 (379.1-697.0) 955.9 (0–2524.2) 698.8 (363.5-1034.0) 0.32
Osteocalcin (pmol/L) 36.4 (26.7-46.0) 32.3 (14.0-50.6) 47.7 (25.7-69.7) 0.50
Osteopontin (ng/mL) 98.1 (86.8-109.4) 124.4 (104.9-143.9) 98.5 (80.3-116.7) 0.31
Osteoprotegerin (pmol/L) 17.5 (14.1-20.9) 12.0 (3.7-20.3) 6.4 (4.3-8.5) 0.003
Matrix GLA protein (nmol/L) 11.5 (10.5-12.5) 9.1 (4.0-14.2) 9.8 (7.9-11.8) 0.13
Fetuin-A (g/L) 0.60 (0.50-0.69) 0.72 (0.39-1.05) 0.68 (0.51-0.85) 0.54
CRP (mg/L) 12.9 (9.3-16.6) 10.6 (7.2-18.1) 8.2 (2.4-14.1) 0.03
IL-6 (pg/mL) 7.5 (5.3-9.6) 6.8 (4.2-8.4) 8.1 (1.0-15.3) 0.68
TNF-α (pg/mL) 11.1 (8.9-13.3) 6.8 (2.5-9.7) 11.4 (7.1-15.7) 0.22
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rence of CAC, while only age was a major (OR = 1.20)
predictor of the occurrence of AAC. Other traditional
risk factors of atherosclerosis, correlated with CAC in
our study, included diabetes and duration of hyperten-
sion therapy. All but one patients with obesity had CAC,
but the limited number of obese patients precluded any
statistical significance. We also failed to prove the asso-
ciation between dyslipidemia and CAC and AAC, prob-
ably as lipid disorders in CKD certainly differs from
those prior to HD therapy and reflects only the current
status and overlapping treatment. We did not analyzethe association between physical activity and calcifica-
tion status as the group had highly heterogeneous age.
Moreover, we did not analyze the long-term nutritional
habits due to the lack of research tools.
The prevalence of CAC (73.1%) is similar as previ-
ously reported - 65-90% [9-12]. However, it was
lower than reported by Goodman et al. in young
adults with 2-time longer dialysis vintage (7 ± 6 years)
[13]. This pointing out the important influence of
long-term vascular wall exposition on uremic milieu,
later confirmed by Raggi et al. [10]. Additionally, in
our study the frequency of calcifications increased
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decade.
Among the most well-known and studied uremic ab-
normalities associated with development of vascular
calcifications were mineral disturbances: hyperphospha-
temia, high CaxP product, secondary hyperparathyroid-
ism and adynamic bone disease. However, we did not
find any difference in serum phosphorous and CaxP
product, measured in a single sample, between patients
with and without calcifications and the relationships be-
tween serum phosphorous and severity of calcifications
in both localizations studied. This is not the only study
that failed to demonstrate such a relation [12,14,15].
However, this observation does not exclude the driving
force of phosphorous in the development of vascular
calcifications as the subgroup with calcifications was sig-
nificantly longer exposed to phosphorous disturbances
(longer hemodialysis vintage). The lack of lower serum
phosphorous concentration in significantly younger sub-
group yet without vascular calcification can be explained
by the more frequent non-adherence of younger patients
to phosphorous binding drugs and diet recommendation
[16]. Another possible explanation is time-dependent
variation of serum phosphorous related to variability of
dietary phosphate consumption, phosphate binder doses
and duration of hemodialysis sessions. Recently Cianciolo
et al. tried to overcome this problem calculating the
period of exposure to phosphorous over 5.5 mg/dl and
CaxP product over 55 mg2/dl2 recorded during last
24 months [11]. In this study the independent contribu-
tion in multivariate regression was only shown for
nondiabetic HD patients. This cited data and results of
our study may suggest that during the last decade an im-
portant improvement of the mineral disturbances
management was obtained, inter alia by dose reduction of
calcium phosphorous binders and active vitamin D
metabolites, introduction of sevelamer hydrochloride and
cinacalcet, recently. The progress in secondary hyperpara-
thyroidism management was associated with increased
frequency of adynamic bone disease (ABD), and the risk
for vascular calcification development [17]. In our
study in subgroup with vascular calcification one of
the four patients had low PTH level that characterize
patients with ABD.
Currently it is suggested that FGF-23 is a very sensitive
marker of phosphorous disturbances. Additionally, an
association between plasma FGF-23 levels and CACS or
AAC were recently reported in studies assessed relatively
small groups of hemodialysis patients with extremely
high FGF-23 levels [18,19]. These interesting data were
not confirmed by the results of lager study performed by
Cianciolo et al. [11] and presented in our paper. It
should be emphasized, that no FGF-23 vascular toxicity
has been demonstrated yet.There are several line of evidence showing that CAC
are associated with systemic inflammation [12,14,15],
as the component of the malnutrition-inflammation-
atherosclerosis syndrome. Atherosclerosis frequently
coexists with systemic inflammation especially in
hemodialysis diabetic patients [20]. Experimental studies
demonstrated that TNF-α in dose-dependent manner in-
duce differentiation of VSMCs into osteoblast-like cells
and stimulate mineral deposition [21]. We have also
shown that patients with CAC and AAC had significantly
higher serum CRP levels but not IL-6 and TNF-α.
However, there was no correlation between circulating in-
flammatory markers levels and calcification scores. Time-
dependent high variability is a potential cause of the
conflicting results.
The process of vascular calcifications has natural inhi-
bitors, such as MGP, osteopontin, osteoprotegerin,
fetuin-A and pyrophosphates [5]. However, in our study
only plasma level of osteoprotegerin was significantly
increased in patient with than without calcification and
was related to their severity. The association between
CAC and higher circulating osteoprotegerin concentra-
tion has been previously revealed by Barreto et al. in HD
patients. The authors suggested that it represents an in-
complete self-defensive response to the progression of
atherosclerosis [22]. Similarly, it has also been shown
that increased serum osteoprotegerin levels correlates
with AACS [23]. Moreover, osteoprotegerin levels were
associated with progression of CACS in HD patients
[24]. The lack of independent contribution to the occur-
rence of CAC and AAC in our study suggest that circu-
lating osteoprotegerin level is rather a marker of
vascular pathology in HD patients.
In our study the assessment of AAC was performed
with own method developed, similar to the evaluation
performed in the CAC. While, in the earlier studies the
assessment was based on the index coverage perimeter
of the aortic wall [14]. We consider, the method used in
our study is more precise. In consequence we detected
higher prevalence of abdominal aorta calcifications than
previously reported. Okuno et al. in abdominal X-ray
imaging shown AAC in 56.6% of hemodialysis patients
[25]. In the large multicenter CORD study including 933
adult hemodialysis patients [26], the prevalence of AAC
was similar to those reported by us (81 vs. 79.9%). In this
study the occurrence of AAC were related to age and
dialysis vintage. While, we were unable to prove the ef-
fect of dialysis vintage on the occurrence and severity of
AAC. On the other hand we showed the association be-
tween diabetes coexistence or smoking and the severity
of calcifications, as was previously observed in the gen-
eral population [27].
Our study shows not only some differences in factors
associated with the occurrence of vascular calcification
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http://www.biomedcentral.com/1471-2369/14/10in elastic (abdominal aorta) and muscular (coronary) ar-
teries but also demonstrate that AAC in HD patients
develops usually in younger age than CAC does. This
statement is also supported by the identification of a
group of 7 patients with isolated AAC. This group of
patients was by more than a decade younger, and
additionally had remarkably shorter hemodialysis vintage
than those with calcifications in both locations. This
may suggest either the different effect of age or dialysis
vintage on the development of vascular calcification in
both locations. Though, the existence of positive correl-
ation between hemodialysis vintage and CAC but not
AAC suggest more deteriorative effect of uremic milieu
on the pathogenesis of coronary vessel pathology. While,
the development of AAC seems to be more dependent
on traditional cardiovascular risk factors (i.e. age). This
interesting observation necessitate further studies.
Our study has some limitations. The main one is the
cross sectional study design and the heterogeneity of the
study group in aspect of CKD causes, age and dialysis
vintage. We cannot exclude that the strong impact of
age does not mask weaker effects of mineral distur-
bances. Additionally, we did not assessed the uncarboxy-
lated MGP fraction, but total MGP, that limits
conclusions of their role for vascular calcification
development. Moreover we did not analyzed the impact
of prior to CKD diagnosis factors related to lifestyle, ex-
cept smoking.Conclusion
1. AAC precedes the occurrence of CAC in HD patients.
2. The exposition to uremic milieu and microinflamma-
tion has more deteriorative effect on the CAC than the
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